Abstract
INTRODUCTION: As a partial mu-opioid receptor agonist, buprenorphine has unique properties that distinguish it from full mu-opioid receptor agonists. In a phase 1 study (ClinicalTrials.gov, NCT03996694), oxycodone administration led to significant, dose-dependent decrease in respiratory drive, whereas buprenorphine buccal film (BBF) did not. Here we report secondary outcomes from that study, including respiratory, pharmacokinetic, and pupillometry assessments. Methods: Healthy individuals who self-identified as recreational opioid users were recruited for this randomized, double-blind, double-dummy, 6-treatment, 6-period, placebo-controlled crossover study to compare effects of BBF (300, 600, and 900 μg), oral immediate-release oxycodone (30 and 60 mg), and placebo on respiratory drive, pharmacokinetics, and pupillometry outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
